Clinical Trials

For women who carry the breast cancer 1 gene mutation. Finding out if removing just the fallopian tubes now and the ovaries later is as good as removing both the tubes and ovaries at the same time for lowering the risk of ovarian cancer in women who have a harmful BRCA1 gene mutation

This study is being done to answer the following question: Can we lower the chance of cancer growing or spreading with the combination of a newer medication and other therapies: We are doing this study because we want to find out if this approach is better or worse than the usual approach for your cancer. The usual approach is defined as care most people get for cancer.

This study is being done to see if adding chemotherapy to the usual treatment for advanced prostate cancer helps patients live longer. The drug is already approved by the FDA for treating prostate cancer. However, it is usually used only after hormonal therapy and apalutamide are no longer working. The study will also look at a test to see if it can help doctors decide which patients might benefit the most from adding the drug. Doctors do not know yet if this test will be useful in making treatment choices. If it is helpful, it could become a regular part of care for men with advanced prostate cancer.

The purpose of this study is to understand if the drug Gleolan can improve the ability to show ovarian cancer tumor tissue and what is the benefit and risk of such during surgery and to understand the safety of the drug Gleolan in patients with ovarian tumors.

(Study is CLOSED at this site) - This study is being done to see if we can possibly shrink or prevent your head and neck cancer from spreading by adding an antibody drug (cetuximab) to your immunotherapy treatment (pembrolizumab).

The purpose of this study is to compare a usual treatment alone to using MEDI4736 (durvalumab) plus the usual treatment. The study approach could shrink your cancer. But, it could also cause side effects, which are described in the risks section below. MEDI4736 (durvalumab) is a type of immunotherapy drug that is already approved by the FDA for use in urothelial cancer. But, most of the time it is not used until platinum-containing chemotherapy, such as cisplatin, stops working for your cancer. This study will help the study doctors find out if this different approach is better than the usual approach. To decide if it is better, the study doctors will be looking at two main factors. They will be investigating if the study approach will increase the number of patients whose cancer is shrunk significantly after surgery. They will also be investigating if the study approach increases the number of patients who do not have the cancer come back or get worse.

This study is for advanced cancer that has become worse following treatment, or advanced cancer for which no standard treatment exists.

(STUDY IS CLOSED AT THIS SITE) This a phase II clinical trial for patients with advanced papillary kidney cancer (renal cell carcinoma), which compares the use of cabozantinib alone versus cabozantinib in combination with atezolizumab.

This is study is treating low tumor burden follicular lymphoma, a type of slow-growing (indolent) blood cancer with a minimal amount of disease present in the body. The purpose of this study is to compare the usual treatment (rituximab) to using the study drug mosunetuzumab.

(CLOSED at this Site) This study wants to find out if a blood test can help doctors decide which patients need more treatment after surgical removal of the bladder, kidney, ureter, or urethra. This blood test looks for small pieces of cancer DNA, called ctDNA, in the blood. If ctDNA is found, it means some cancer cells may still be in the body. The trial will give some patients an extra medicine, called immunotherapy, to help their immune system find and kill any remaining cancer. This will help doctors learn if using the blood test to guide treatment will help patients live longer without their cancer coming back.